Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pelcitoclax + chidamide
- Development stage
- Phase 2
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pelcitoclax + chidamide is a combination therapy under investigation for the treatment of cancer. **Pelcitoclax** is a selective BCL-2/BCL-xL inhibitor (also referred to as APG-1252), designed to induce apoptosis in tumor cells by antagonizing anti-apoptotic proteins BCL-2 and BCL-xL. **Chidamide** is a benzamide class histone deacetylase (HDAC) inhibitor, active against HDAC1, HDAC2, HDAC3, and HDAC10. Chidamide induces tumor cell apoptosis, cell cycle arrest, and enhances antitumor immune responses, and has been approved in China for relapsed or refractory peripheral T-cell lymphoma and investigated widely in hematological and solid malignancies[2][3][4]. The combination aims to synergistically promote apoptosis and sensitize tumor cells through both anti-apoptotic protein and epigenetic modulation pathways.
- Other names
- CS055CS-055CS 055HBI-8000HBI8000HBI 8000
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on pelcitoclax + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pelcitoclax + chidamide.